var data={"title":"Piperacillin (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Piperacillin (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6783?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=piperacillin-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Piperacillin (United States: Not available): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3000477\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Piperacillin for Injection</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210349\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Penicillin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210309\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Community-acquired pneumonia:</b> IM, IV: Usual dosage: 6 to 8 g daily (100 to 125 mg/kg daily) in divided doses every 6 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Severe infections (eg, gynecologic, intra-abdominal, nosocomial pneumonia, septicemia, skin/soft tissue):</b> IV: Usual dosage: 12 to 18 g daily (200 to 300 mg/kg daily) in divided doses every 4 to 6 hours (maximum: 24 g daily)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urethritis (gonococcal, uncomplicated):</b> IM: 2 g once (<b>Note:</b> Administer probenecid 30 minutes prior to piperacillin)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urinary tract infection (complicated):</b> IV: Usual dosage: 8 to 16 g daily (125 to 200 mg/kg daily) in divided doses every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urinary tract infection (uncomplicated):</b> IM, IV: Usual dosage: 6 to 8 g daily (100 to 125 mg/kg daily) in divided doses every 6 to 12 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50990800\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &gt;40 mL/minute or serum creatinine 1.5 to 3 mg/dL: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl 20-40 mL/minute or serum creatinine 3.1 to 5 mg/dL:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Urinary tract infection (uncomplicated): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Urinary tract infection (complicated): 3 g every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe systemic infection: 4 g every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &lt;20 mL/minute or serum creatinine &gt;5 mg/dL:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Urinary tract infection (complicated/uncomplicated): 3 g every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe systemic infection: 4 g every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: Severe systemic infection: 2 g every 8 hours; administer 1 g supplemental dose after each dialysis session; dialyzable (30% to 50%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50987996\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210331\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">\n      <b>Usual dosage range:</b> Children &ge;12 years and Adolescents: IM, IV: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51154215\" class=\"block dorp drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Pediatric)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children &ge;12 years and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; however, the following have been used by some clinicians (Aronoff 2007): <b>Note:</b> Dosage recommendations are based on the piperacillin component. Dosing based on a usual dose of 200 to 300 mg piperacillin kg/<b>day</b> in divided doses every 6 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GFR 30 to 50 mL/minute/1.73 m<sup>2</sup>: 35 to 50 mg piperacillin/kg/dose every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GFR &lt;30 mL/minute/1.73 m<sup>2</sup>: 35 to 50 mg piperacillin/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermittent hemodialysis (IHD): Removed by hemodialysis; dosing adjustment suggested</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51204760\" class=\"block dohp drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer&rsquo;s labeling; based on experience with piperacillin/tazobactam, no adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210310\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Dosage adjustment may be necessary for renal impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46742490\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution Reconstituted, Injection: 2 g, 3 g, 4 g [contains sodium 42.5 mg (1.85 mEq) per g]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23325456\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Not available in the US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210288\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Rapid administration can lead to seizures. Administer by IV injection over 3 to 5 minutes or by intermittent infusion over 20 to 30 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: IM injection should be administered into the upper outer quadrant of the buttocks. Do not administer more than 2 g per IM injection site.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210287\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Not approved in the US</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Infection: </b>Treatment of infection caused by susceptible gram-negative/gram-positive aerobic and anaerobic bacteria including intra-abdominal infections, septicemia, lower respiratory tract infections, skin and soft tissue infections, bone and joint infections, gynecological infections, urinary tract infections (complicated and uncomplicated), and urethritis (uncomplicated); may also be used to treat mixed infections due to susceptible streptococci</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210275\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Local thrombophlebitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Confusion, drowsiness, myoclonus, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash, toxic epidermal necrolysis, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Electrolyte disturbance, hypokalemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Abnormal platelet aggregation (high doses), agranulocytosis, hemolytic anemia, pancytopenia, positive direct Coombs test, prolonged prothrombin time (high doses)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Jarisch-Herxheimer reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Acute interstitial nephritis, acute renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210291\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to any of the penicillins and/or cephalosporins or any component of the formulation; hypersensitivity to local anesthetics of the amide type (when reconstituted with lidocaine for IM use)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210272\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anaphylactoid/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactoid) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity, history of sensitivity to multiple allergens, or previous IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria). Use with caution in asthmatic patients. Discontinue if hypersensitivity occurs; initiate appropriate rescue treatment for serious hypersensitivity reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bleeding disorders: Particularly in patients with renal impairment, bleeding disorders have been observed; discontinue if thrombocytopenia or bleeding occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Leukopenia/neutropenia: During prolonged use, leukopenia and neutropenia have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular disease: Use with caution particularly in sodium-restricted patients receiving prolonged therapy; formulation contains 42.5 mg of sodium per gram. Monitor electrolyte status and cardiac function with prolonged therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cystic fibrosis: An increased frequency of fever and rash has been reported in patients with cystic fibrosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Infectious mononucleosis: Patients with infectious mononucleosis have developed rash during therapy with other penicillins (eg, ampicillin, amoxicillin).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment, due to sodium load and adverse effects (hematologic, neuropsychological changes); dosage adjustment recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Seizure disorders: High drug levels, particularly in the presence of renal impairment, may increase risk of seizures. Use with caution in patients with a history of seizure disorder.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Syphilis: Symptoms of syphilis may be masked or delayed in patients receiving high-dose antimicrobial treatment of gonorrhea; patients with gonorrhea should be evaluated for syphilis prior to initiating antimicrobial treatment and if syphilis is suspected, continue serologic testing monthly for at least 4 months.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299883\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210277\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9775&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acemetacin: May increase the serum concentration of Penicillins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Penicillins may decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flucloxacillin: Piperacillin may increase the serum concentration of Flucloxacillin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Penicillins may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Penicillins. Management: Avoid the routine use of penicillins and probenecid, but this combination may be used advantageously in select cases with careful monitoring. Monitor for toxic effects of penicillins if probenecid is initiated or the dose is increased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: May diminish the therapeutic effect of Penicillins.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vancomycin: Piperacillin may enhance the nephrotoxic effect of Vancomycin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vecuronium: Piperacillin may enhance the neuromuscular-blocking effect of Vecuronium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5719723\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Piperacillin crosses the placenta and distributes into the amniotic fluid (Brown, 1990; Heikkil&auml;, 1991). Due to pregnancy-induced physiologic changes, some pharmacokinetic parameters of piperacillin may be altered. At term, the apparent volume of distribution of piperacillin is increased and peak concentrations are significantly lower. Total clearance is normal to increased at term (Heikkil&auml;, 1991; Voight, 1985). These changes continue into the early postpartum period (Charles, 1985; Martens, 1987).  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5707585\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Small amounts of piperacillin are excreted in breast milk. The manufacturer recommends that caution be exercised when administering piperacillin to nursing women. Nondose-related effects could include modification of bowel flora. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210294\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Sodium content of 1 g: 1.85 mEq (42.5 mg)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210282\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Observe for signs and symptoms of anaphylaxis during first dose; with extended therapy consider monitoring of electrolytes and cardiac status (patients with impaired cardiac function), serum creatinine, BUN, hepatic function, and CBC.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210271\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs); which in turn inhibit the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F210290\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: IM: Rapid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~16% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination (dose dependent; prolonged with renal impairment): Adults: ~1 hour (decreased in patients with cystic fibrosis)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: IM: 30 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Primarily urine; partially feces</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038768\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acopex (KR);</li>\n      <li>Isipen (HR, PL);</li>\n      <li>Pentcillin (JP);</li>\n      <li>Peracillin (KR);</li>\n      <li>Peracin (TH);</li>\n      <li>Picillina (TW);</li>\n      <li>Pipcil (LU);</li>\n      <li>Piperacillin (PL);</li>\n      <li>Pipracil (IN);</li>\n      <li>Pipracin (IL);</li>\n      <li>Pipraks (CY, EG, IQ, IR, JO, KW, LB, LY, OM, SY, YE);</li>\n      <li>Pipril (AE, BH, EG, GR, HN, HR, IE, PK, QA, SA);</li>\n      <li>Prisutomycin (TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al.<i> Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed</i>. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brown CE, Christmas JT, and Bawdon RE. Placental transfer of cefazolin and piperacillin in pregnancies remote from term complicated by Rh isoimmunization. <i>Am J Obstet Gynecol</i>. 1990;163(3):938-943.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/2119561/pubmed\" target=\"_blank\" id=\"2119561\">2119561</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Charles D, Larsen B. Pharmacokinetics of piperacillin in the postpartum patient. <i>Gynecol Obstet Invest</i>. 1985;20(4):194-198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/4085922/pubmed\" target=\"_blank\" id=\"4085922\">4085922</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Donowitz GR and Mandell GL, &ldquo;Beta-Lactam Antibiotics,&rdquo; <i>N Engl J Med</i>, 1988, 318(7):419-26 and 318(8):490-500.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/3277054/pubmed\" target=\"_blank\" id=\"3277054\">3277054</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dowell JA, Korth-Bradley J, Milisci M, et al, &quot;Evaluating Possible Pharmacokinetic Interactions Between Tobramycin, Piperacillin, and a Combination of Piperacillin and Tazobactam in Patients With Various Degrees of Renal Impairment,&quot; <i>J Clin Pharmacol</i>, 2001, 41:979-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/11549103/pubmed\" target=\"_blank\" id=\"11549103\">11549103</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Farchione LA, &quot;Inactivation of Aminoglycosides by Penicillins,&quot; <i>J Antimicrob Chemother</i>, 1981, 8(Suppl A):27-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/7263563/pubmed\" target=\"_blank\" id=\"7263563\">7263563</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fuchs PC, Stickel S, Anderson PH, et al, &quot;<i>In Vitro</i> Inactivation of Aminoglycosides by Sulbactam, Other Beta-Lactams, and Sulbactam-Beta-Lactam Combinations,&quot; <i>Antimicrob Agents Chemother</i>, 1991, 35(1):182-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/2014975/pubmed\" target=\"_blank\" id=\"2014975\">2014975</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Halstenson CE, Wong MO, Herman CS, et al, &quot;Effect of Concomitant Administration of Piperacillin on the Dispositions on Isepamicin and Gentamicin in Patients With End-Stage Renal Disease,&quot; <i>Antimicrob Agents Chemother</i>, 1992, 36(9):1832-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/1416875/pubmed\" target=\"_blank\" id=\"1416875\">1416875</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heikkil&auml; A, Erkkola R. Pharmacokinetics of piperacillin during pregnancy. <i>J Antimicrob Chemother</i>. 1991; 28(3):419-423.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/1960122/pubmed\" target=\"_blank\" id=\"1960122\">1960122</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hitt CM, Patel KB, Nicolau DP, et al, &quot;Influence of Piperacillin-Tazobactam on Pharmacokinetics of Gentamicin Given Once Daily,&quot; <i>Am J Health Syst Pharm</i>, 1997, 54(23):2704-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/9408514/pubmed\" target=\"_blank\" id=\"9408514\">9408514</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Konishi H, Goto M, Nakamoto Y, et al, &quot;Tobramycin Inactivation by Carbenicillin, Ticarcillin, and Piperacillin,&quot; <i>Antimicrob Agents Chemother</i>, 1983, 23(5):653-57.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/6223576/pubmed\" target=\"_blank\" id=\"6223576\">6223576</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lau A, Lee M, Flascha S, et al, &quot;Effect of Piperacillin on Tobramycin Pharmacokinetics in Patients with Normal Renal Function,&quot; <i>Antimicrob Agents Chemother</i>, 1983, 24(4):533-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/6651279/pubmed\" target=\"_blank\" id=\"6651279\">6651279</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Martens MG, Faro S, Feldman S, et al. Pharmacokinetics of the acyclureidopenicillins piperacillin and mezlocillin in the postpartum patient. <i>Antimicrob Agents Chemother</i>. 1987; 31(12):2015-2017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/3439808/pubmed\" target=\"_blank\" id=\"3439808\">3439808</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Russoe ME and Atkins-Thor E, &quot;Gentamicin and Ticarcillin in Subjects With End-Stage Renal Disease. Comparison of Two Assay Methods and Evaluation of Inactivation Rate,&quot; <i>Clin Nephrol</i>, 1981, 15(4):175-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/7237864/pubmed\" target=\"_blank\" id=\"7237864\">7237864</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tan JS and File TM Jr, &ldquo;Antipseudomonal Penicillins,&rdquo; <i>Med Clin North Am</i>, 1995, 79(4):679-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/7791416/pubmed\" target=\"_blank\" id=\"7791416\">7791416</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thompson MIB, Russo ME, Saxon BJ, et al, &quot;Gentamicin Inactivation by Piperacillin or Carbenicillin in Patients With End-Stage Renal Disease,&quot; <i>Antimicrob Agents Chemother</i>, 1982, 21(2):268-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/6462107/pubmed\" target=\"_blank\" id=\"6462107\">6462107</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Viollier AF, Standiford HC, Drusano GL, et al, &quot;Comparative Pharmacokinetics and Serum Bactericidal Activity of Mezlocillin, Ticarcillin and Piperacillin, With and Without Gentamicin,&quot; <i>J Antimicrob Chemother</i>, 1985, 15(5):597-606.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/4008387/pubmed\" target=\"_blank\" id=\"4008387\">4008387</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Voigt R, Schr&ouml;der S, Peiker G. Pharmacokinetic studies of azlocillin and piperacillin during late pregnancy. <i>Chemotherapy</i>. 1985;31(6):417-424.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/3908007/pubmed\" target=\"_blank\" id=\"3908007\">3908007</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walterspiel JN, Feldman S, Van R, et al, &quot;Comparative Inactivation of Isepamicin, Amikacin, and Gentamicin by Nine Beta-Lactams and Two Beta-Lactamase Inhibitors, Cilastatin and Heparin,&quot; <i>Antimicrob Agents Chemother</i>, 1991, 35(9):1875-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/1952861/pubmed\" target=\"_blank\" id=\"1952861\">1952861</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wright AJ, &ldquo;The Penicillins,&rdquo; <i>Mayo Clin Proc</i>, 1999, 74(3):290-307.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/10090000/pubmed\" target=\"_blank\" id=\"10090000\">10090000</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yoshikawa TT, &ldquo;Antimicrobial Therapy for the Elderly Patient,&rdquo; <i>J Am Geriatr Soc</i>, 1990, 38(12):1353-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/piperacillin-united-states-not-available-drug-information/abstract-text/2254575/pubmed\" target=\"_blank\" id=\"2254575\">2254575</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9775 Version 105.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F3000477\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F210349\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F210309\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50990800\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50987996\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F210331\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Pediatric)\" href=\"#F51154215\" class=\"outlineLink\">Dosing: Renal Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Pediatric)\" href=\"#F51204760\" class=\"outlineLink\">Dosing: Hepatic Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F210310\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F46742490\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F23325456\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F210288\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F210287\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F210275\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F210291\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F210272\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299883\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F210277\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5719723\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F5707585\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F210294\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F210282\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F210271\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F210290\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038768\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9775|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=piperacillin-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Piperacillin (United States: Not available): Patient drug information</a></li></ul></div></div>","javascript":null}